NBIX - Neurocrine Biosciences, Inc.
| Previous close | 94.03 |
| Open | 94.03 |
| Bid | 93.40 x 800 |
| Ask | 93.46 x 1100 |
| Day's range | 93.17 - 94.32 |
| 52-week range | 88.38 - 129.29 |
| Volume | |
| Avg. volume | 704,544 |
| Market cap | 9.106B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 150.52 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | N/A |
- Simply Wall St.
Are Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
It is hard to get excited after looking at Neurocrine Biosciences' (NASDAQ:NBIX) recent performance, when its stock has...
- Zacks
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: Zoetis (ZTS) Q1 Earnings Expected to Decline
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Neurocrine Biosciences Full Year 2022 Earnings: EPS Misses Expectations
Neurocrine Biosciences ( NASDAQ:NBIX ) Full Year 2022 Results Key Financial Results Revenue: US$1.49b (up 31% from FY...
- Simply Wall St.
Investors one-year returns in Neurocrine Biosciences (NASDAQ:NBIX) have not grown faster than the company's underlying earnings growth
It hasn't been the best quarter for Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) shareholders, since the share price...
- Zacks
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Why Voyager Therapeutics Stock Is Sinking This Week
Shares of the gene therapy company Voyager Therapeutics (NASDAQ: VYGR) were down by a little over 18% from their intraweek high as of 11:44 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. Rather, Voyager's shares seem to be reverting to the mean following their enormous run-up earlier this month. As a refresher, the biotech's shares spiked by as much as 76% during the first two weeks of January as a result of the company's lucrative gene therapy deal with Neurocrine Biosciences (NASDAQ: NBIX).
- Simply Wall St.
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Most readers would already be aware that Neurocrine Biosciences' (NASDAQ:NBIX) stock increased significantly by 10...
- Zacks
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
- Zacks
Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows
Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.
- Zacks
Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?
Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
- Zacks
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
3 Top Biotech Stocks Defying the Bear Market
If there is, it's wrong too -- at least when applied to the stock market. As a case in point, here are three top biotech stocks that are defying the bear market. Few stocks in any sector have outperformed Vertex Pharmaceuticals (NASDAQ: VRTX) in 2022.
- Motley Fool
3 Growth Stocks That Are Crushing It This Year
The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down more than 19%, even though both have rallied a bit in the past few months. Contrast that with Vertex Pharmaceuticals (NASDAQ: VRTX), Axsome Therapeutics (NASDAQ: AXSM), and Neurocrine Biosciences (NASDAQ: NBIX), as all are up 20% or more this year.
- Simply Wall St.
Investing in Neurocrine Biosciences (NASDAQ:NBIX) five years ago would have delivered you a 78% gain
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
- Motley Fool
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript
With me are Kevin Gorman, our chief executive officer; Matthew Abernethy, our chief financial officer; Eiry Roberts, our chief medical officer; Eric Benevich, our chief commercial officer; and Kyle Gano, our chief business development and strategy officer. During a call, we will be making forward-looking statements.
- Zacks
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.
- Zacks
Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?
Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
- Simply Wall St.
Has Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Most readers would already be aware that Neurocrine Biosciences' (NASDAQ:NBIX) stock increased significantly by 5.1...
